Poor Prognosis Metastatic Gestational Trophoblastic Tumor
5
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
1 terminated out of 5 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant